BioCentury | Jul 9, 2015
Product R&D

Downstream without a NET

ModiQuest B.V. has discovered that its therapeutic mAb against citrullinated histones has the potential to treat autoimmune diseases by inhibiting the formation of neutrophil extracellular traps that play a role in the pathogenesis of autoimmunity....
BioCentury | Dec 19, 2013
Translation in Brief

Translational tidbits

...to jointly identify and fund early stage life science technologies from MaRS' 16 member institutions ModiQuest Research B.V....
BioCentury | Nov 11, 2013
Company News

ModiQuest Research, Beckman Research Institute of the City of Hope deal

...not disclose financial details, and the institute did not provide comment in time for publication. ModiQuest Research B.V....
Items per page:
1 - 3 of 3
BioCentury | Jul 9, 2015
Product R&D

Downstream without a NET

ModiQuest B.V. has discovered that its therapeutic mAb against citrullinated histones has the potential to treat autoimmune diseases by inhibiting the formation of neutrophil extracellular traps that play a role in the pathogenesis of autoimmunity....
BioCentury | Dec 19, 2013
Translation in Brief

Translational tidbits

...to jointly identify and fund early stage life science technologies from MaRS' 16 member institutions ModiQuest Research B.V....
BioCentury | Nov 11, 2013
Company News

ModiQuest Research, Beckman Research Institute of the City of Hope deal

...not disclose financial details, and the institute did not provide comment in time for publication. ModiQuest Research B.V....
Items per page:
1 - 3 of 3